Literature DB >> 26795607

The effect of delaying nephrectomy on oncologic outcomes in patients with renal tumors greater than 4cm.

Roy Mano1, Emily A Vertosick2, Abraham Ari Hakimi3, Itay A Sternberg3, Daniel D Sjoberg2, Melanie Bernstein3, Guido Dalbagni3, Jonathan A Coleman3, Paul Russo3.   

Abstract

OBJECTIVES: Delaying nephrectomy<3 months does not adversely affect treatment outcome of renal tumors. Whether surgical waiting time (SWT; time from diagnosis to surgery)>3 months affects treatment outcome for large renal masses has not been well studied. We aimed to evaluate if SWT is associated with treatment outcome of renal masses >4cm and identify patients who are more likely to experience prolonged SWT.
MATERIALS AND METHODS: Data from 1,484 patients undergoing radical or partial nephrectomy at a single institution for a nonmetastatic renal mass>4cm between 1995 and 2013 were reviewed. Patients with benign tumors and incomplete preoperative data were excluded. The association between SWT and disease upstaging at the time of surgery and recurrence at 2 and 5 years was assessed using logistic regression. Cancer-specific survival (CSS) and overall survival were assessed with landmark survival analyses and multivariable Cox proportional hazards models. All analyses were adjusted for patient and tumor characteristics.
RESULTS: Of the final cohort of 1,278 patients, 267 (21%) had SWT>3 months. Patients with larger, symptomatic tumors had shorter SWT. Median follow-up for survivors was 3.8 years (interquartile range: 1.5-7.4). On multivariable analysis, SWT was not associated with disease upstaging, recurrence, or CSS. Longer SWT was associated with decreased overall survival (hazard ratio = 1.17; 95% CI: 1.08-1.27; P = 0.0002). Sex and tumor size, histology, and presentation were associated with disease upstaging, recurrence, and CSS. The most common cause for surgical delay>3 months was evaluation and treatment of comorbidities.
CONCLUSION: Patient and tumor characteristics, rather than SWT, were associated with disease upstaging, recurrence, and CSS, and should guide the decision to delay surgery when treating nonmetastatic renal tumors>4cm.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Nephrectomy; Outcome prediction; Renal cell carcinoma; Surgical treatment delay

Mesh:

Year:  2016        PMID: 26795607      PMCID: PMC4834237          DOI: 10.1016/j.urolonc.2015.12.001

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  26 in total

Review 1.  Does prolonging the time to renal cancer surgery affect long-term cancer control: a systematic review of the literature.

Authors:  Michael Jewett; Ricardo Rendon; George Dranitsaris; Darrel Drachenberg; Simon Tanguay; Bryan Donnelly; Neil Fleshner
Journal:  Can J Urol       Date:  2006-06       Impact factor: 1.344

2.  Metastatic potential in renal cell carcinomas ≤7 cm: Swedish Kidney Cancer Quality Register data.

Authors:  Eirikur Guðmundsson; Henrik Hellborg; Sven Lundstam; Stina Erikson; Börje Ljungberg
Journal:  Eur Urol       Date:  2011-07-01       Impact factor: 20.096

3.  Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance.

Authors:  Ross J Mason; Mohamed Abdolell; Greg Trottier; Christopher Pringle; Joseph G Lawen; David G Bell; Michael A S Jewett; Laurence Klotz; Ricardo A Rendon
Journal:  Eur Urol       Date:  2011-02-22       Impact factor: 20.096

4.  The impact of delaying radical nephrectomy for stage II or higher renal cell carcinoma.

Authors:  Kwang Hyun Kim; Dalsan You; In Gab Jeong; Cheryn Song; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  J Cancer Res Clin Oncol       Date:  2012-05-01       Impact factor: 4.553

5.  How long can patients with renal cell carcinoma wait for surgery without compromising pathological outcomes?

Authors:  Carlos H Martínez; Paul Martin; Venu Chalasani; Andrew K Williams; Patrick P W Luke; Jonathan I Izawa; Joseph L Chin; Larry Stitt; Stephen E Pautler
Journal:  Can Urol Assoc J       Date:  2011-03-01       Impact factor: 1.862

6.  Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage.

Authors:  Kirk A Keegan; Clayton W Schupp; Karim Chamie; Nicholas J Hellenthal; Christopher P Evans; Theresa M Koppie
Journal:  J Urol       Date:  2012-06-13       Impact factor: 7.450

Review 7.  EAU guidelines on renal cell carcinoma: 2014 update.

Authors:  Borje Ljungberg; Karim Bensalah; Steven Canfield; Saeed Dabestani; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Peter Mulders; Thomas Powles; Michael Staehler; Alessandro Volpe; Axel Bex
Journal:  Eur Urol       Date:  2015-01-21       Impact factor: 20.096

8.  Incidentally discovered renal masses: oncological and perioperative outcomes in patients with delayed surgical intervention.

Authors:  Soroush Rais-Bahrami; Thomas J Guzzo; Thomas W Jarrett; Louis R Kavoussi; Mohamad E Allaf
Journal:  BJU Int       Date:  2009-02-23       Impact factor: 5.588

9.  The growth rate of large renal masses opposes active surveillance.

Authors:  Michael Staehler; Nicolas Haseke; Thomas Stadler; Ekaterina Zilinberg; Cordula Nordhaus; Philip Nuhn; Wael Y Khoder; Alexander Karl; Christian G Stief
Journal:  BJU Int       Date:  2009-09-14       Impact factor: 5.588

10.  Longer wait times increase overall mortality in patients with bladder cancer.

Authors:  Girish S Kulkarni; David R Urbach; Peter C Austin; Neil E Fleshner; Andreas Laupacis
Journal:  J Urol       Date:  2009-08-14       Impact factor: 7.450

View more
  8 in total

1.  Systemic therapy for metastatic renal cell carcinoma-is timing everything?

Authors:  Ritesh R Kotecha; Martin H Voss
Journal:  Ann Transl Med       Date:  2019-09

2.  Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study.

Authors:  Amit Sud; Bethany Torr; Michael E Jones; John Broggio; Stephen Scott; Chey Loveday; Alice Garrett; Firza Gronthoud; David L Nicol; Shaman Jhanji; Stephen A Boyce; Matthew Williams; Elio Riboli; David C Muller; Emma Kipps; James Larkin; Neal Navani; Charles Swanton; Georgios Lyratzopoulos; Ethna McFerran; Mark Lawler; Richard Houlston; Clare Turnbull
Journal:  Lancet Oncol       Date:  2020-07-20       Impact factor: 41.316

3.  Triage of urology service to cope with COVID-19 pandemic: A single institution study.

Authors:  Muhammad Waqar; Kelly Ong; Amr Moubasher; Omer Farooq Rehman; Kamran Faisal Bhopal; Jonathan Makanjuola
Journal:  EXCLI J       Date:  2021-01-07       Impact factor: 4.068

4.  Delayed surgery for localised and metastatic renal cell carcinoma: a systematic review and meta-analysis for the COVID-19 pandemic.

Authors:  Vinson Wai-Shun Chan; Wei Shen Tan; Jeffrey J Leow; Wei Phin Tan; William Lay Keat Ong; Peter Ka-Fung Chiu; Pratik Gurung; Giacomo Maria Pirola; Luca Orecchia; Matthew Ping Chao Liew; Hsiang-Ying Lee; Yuding Wang; I-Hsuan Alan Chen; Daniele Castellani; Marcelo Langer Wroclawski; Nikhil Mayor; Niranjan J Sathianathen; Isaac Braga; Zhenbang Liu; Dora Moon; Kari Tikkinen; Ashish Kamat; Max Meng; Vincenzo Ficarra; Gianluca Giannarini; Jeremy Yuen-Chun Teoh
Journal:  World J Urol       Date:  2021-05-24       Impact factor: 4.226

5.  Nephrectomy Delay of More than 10 Weeks from Diagnosis Is Associated with Decreased Overall Survival in pT3 RCC.

Authors:  Jiping Zeng; Ken Batai; Benjamin R Lee
Journal:  J Kidney Cancer VHL       Date:  2021-06-14

Review 6.  Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic.

Authors:  Christopher J D Wallis; Giacomo Novara; Laura Marandino; Axel Bex; Ashish M Kamat; R Jeffrey Karnes; Todd M Morgan; Nicolas Mottet; Silke Gillessen; Alberto Bossi; Morgan Roupret; Thomas Powles; Andrea Necchi; James W F Catto; Zachary Klaassen
Journal:  Eur Urol       Date:  2020-05-03       Impact factor: 20.096

7.  Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond.

Authors:  Arnav Srivastava; Hiren V Patel; Sinae Kim; Brian Shinder; Joshua Sterling; Alexandra L Tabakin; Charles F Polotti; Biren Saraiya; Tina Mayer; Isaac Y Kim; Saum Ghodoussipour; Hiten D Patel; Thomas L Jang; Eric A Singer
Journal:  Urol Oncol       Date:  2020-10-20       Impact factor: 3.498

8.  What is Elective Oncologic Surgery in the Time of COVID-19? A Literature Review of the Impact of Surgical Delays on Outcomes in Patients with Cancer.

Authors:  Denise Garcia; Julie B Siegel; David A Mahvi; Biqi Zhang; David M Mahvi; E Ramsay Camp; Whitney Graybill; Stephen J Savage; Antonio Giordano; Sara Giordano; Denise Carneiro-Pla; Mahsa Javid; Aaron P Lesher; Andrea Abbott; Nancy Klauber DeMore
Journal:  Clin Oncol Res       Date:  2020-06-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.